A few days before a report on its expected savings, the director of Health Insurance, Thomas Fatôme, pointed out on Monday “the weight of chronic diseases” in its expenses, whose data by pathology will be accessible from Tuesday via an open data site.
The trend is confirmed year after year: “We see a concentration of health spending around chronic diseases”said Mr. Fatôme during a press presentation of the new site “Data pathologies” tracing the reimbursements for 57 categories of diseases, by region or department, from 2015 to 2020.
The most recent figures show a total of 168 billion spent on the care of more than 66 million patients, of which 104 billion for chronic diseases, or 62%.
A share of an increase of one point compared to 2019, mainly due to the fall in hospitalizations “punctual” during confinements due to the first waves of Covid-19.
But the analysis over several years highlights “Extremely Heavy Factors Pushing Up”, said Mr. Fatome. In five years, the number of patients has increased by 440,000 for diabetes and 540,000 for cardiovascular disease.
At the same time, the cost of treatments jumped 18% for “active cancers” and up to 50% for the lung, with the advent of new treatments such as immunotherapy. “Good news for patient care”acknowledged the boss of the Health Insurance, assuring not to be “not to say it’s too expensive, but to make it clear”.
Also a way to prepare the ground before its annual report “Expenditures and products”, which aims to propose to the government ways to control health spending, upstream of the budget of the Secu presented in the fall.
Without deflowering his expected proposals in late June or early July, he said “The debate on health policy is all the more relevant because it is based on substantiated data.”adding that “Our responsibility is to provoke this debate”.